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AutoimmunityAlopecia areata (AA), a non-scarring inﬂammatory hair loss disorder, is a complex disease determined by genetic
and environmental factors that remain largely unknown. Re-analysis of genome-wide microarray data in 9
patient blood and 10 skin samples revealed transcriptional “hot spots” at chromosomes 1q21–q32,
11q12–q14, and 16p13–p13.3 (blood) and 6p21.3, 12q12–q13, and 17q12–q24 (skin) harboring high densities
of dysregulated genes. We then integrated AA associated gene expression proﬁles with previous genome-wide
genetic analyses to identify a subset of 112 dysregulated genes that map to putative susceptibility loci. Finally,
we analyzed AA patients stratiﬁed by deﬁned clinical characteristics, including a history of atopy, autoimmune
disease, and nail disease, thus deconstructing the clinical heterogeneity observed among AA patients. Integrated
chromosomal and transcriptional proﬁling identiﬁed several dysregulated chromosomal regions and genes
representing an enriched set of biomarkers relevant to AA pathogenesis and clinical heterogeneity.rights reserved.© 2011 Elsevier Inc. All rights reserved.1. Introduction
Alopecia areata (AA) is a relapsing, remitting disorder of
non-scarring hair loss affecting 4.5 million people in the United States,
with a lifetime prevalence of 1.7% [1]. AA can affect any hair-bearing
surface, most commonly the scalp, and has a peak incidence in the
second and third decades of life. Although a generally benign condition,
AA patients exhibit signiﬁcant clinical heterogeneity, evidenced by an
association with atopic disease, an increased incidence of concomitant
autoimmune conditions, and nail involvement in signiﬁcant, but unpre-
dictable subsets of patients [2,3]. Diseases of atopy affect up to 60% of AA
patients [4], and a recent study revealed that patients with a history of
atopic dermatitis (AD) or autoimmune disease are, in turn, at an in-
creased risk of developing AA [5]. Twelve percent of AA patients devel-
op co-existing autoimmune diseases; predominantly thyroid disease,
but also vitiligo and pernicious anemia, among other conditions [2].
Moreover, up to two-thirds of AA patients have nail involvement [6].
The molecular genetics underlying this clinical heterogeneity has been
relatively unstudied [7].
The etiopathogenesis of this relatively common disorder is not well
understood. Several studiesmake a compelling argument for a complex,
polygenic basis for disease supported by: (a) a nearly 20% positive fam-
ily history [8], (b) 55% twin concordance [9,10], (c) familial aggregation[8], and (d) several HLA associations [11,12]. These studies suggest a
strong genetic predisposition to disease that may be triggered by vari-
ous mechanisms such as environmental factors [13] and psychological
stress [14]. Moreover, recent genome wide linkage and association
studies (GWAS) have suggested potential susceptibility loci for more
targeted pathophysiologic studies [15,16]. A challenge to unraveling
the complex interplay of genes and environment has been the paucity
of approaches that integrate biological and clinical information across
genetic, genomic, and transcriptional levels.
Recently, we demonstrated that peripheral blood gene expression
can distinguish AA patients based on familial association to disease,
presence of disease, and clinical extent of disease [17]. Coupled with
our recent analysis of gene expression proﬁling in AA lesional skin
[18], microarrays demonstrate promising utility in themolecular classi-
ﬁcation of disease heterogeneity. Previous studies have shown that
mRNA levels may be heritable traits useful for genetic analysis, thus
serving as possible ‘representative phenotypes’ between genetic sus-
ceptibility and clinically observable traits or diseases [19,20]. Taken to-
gether, we posit that combining information on gene expression,
genetics, and clinical manifestation may help clarify the molecular un-
derpinnings of multi-factorial diseases such as AA.
In this study, microarray transcriptional analysis in peripheral blood
and lesional skin of AA patients and controls was used to generate lists
of disease-related differentially expressed genes (DEGs) and identify
transcriptional “hot spots” within chromosomal locations at which
DEGs map with statistically increased frequency. These data were
then compared with suggested AA susceptibility loci to identify an
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impact on disease expression. We then examined gene expression
data from the blood of AA patients with and without (1) a history of
atopy, (2) concurrent autoimmune disease, and (3) nail involvement
to help guide the identiﬁcation of functional pathways and chromosom-
al loci relevant to these three clinical variables. Our study illuminates
key consensus and/or suggested susceptibility loci/regions associated
with autoimmunity and atopy that are linked to functional conse-
quences in terms of altered gene expression. These data impact our
broader understanding of the genetic overlap between atopy and auto-
immunity, and provide an improved framework to better bridge the gap
between genes and clinical consequence.2. Results
2.1. Gene expression analysis reveals associations within suggested AA
susceptibility loci and identiﬁes novel transcriptional ‘hot spots’
We previously examined a total of 20 human skin biopsies
(10 lesional, 10 non-lesional) and 14 peripheral blood samples (9 AA,
5 unaffected relative controls) to generate AA associated gene expres-
sion proﬁles [17,18]. After normalization per gene per chip, statistical
comparison generated 363 skin DEGs and 882 blood DEGs distinguish-
ing AA from controls. In this study, we merged our AA expression data
with existing AA genetic data fromprevious studies. First, we annotated
blood and skin DEGs locatedwithin the chromosomal regions identiﬁed
as potential AA susceptibility loci in recent association and linkage stud-
ies [15,16] to illuminate potential functional correlates of genetic asso-
ciations. A total of 112 AA DEGs, 76 blood and 36 skin, were found to
mapwithin these regions (Table 1). Functional annotation and pathway
analysis of these overlapping DEGs, generated by the DAVID database
and PubMed literature searches, highlights genes involved in cell prolif-
eration, Wnt signaling, anti-apoptosis, and chemokine signaling.Table 1
Transcriptionally dysregulated genes within putative AA susceptibility loci. DEGs found
within putative AA susceptibility loci [15,16], annotated by respective chromosomal
loci. Blue font coloring indicates down-regulation in AA patient blood and skin,
respectively.
Blood Skin
2q33.2 IDH1, PARD3B, RAPH1, SF3B1
4q27 BBS7
6p21 ANKS1A, BTN3A3, FKBP5,HCG18,
HSPA6, RN7SK, RPS15A, SRPK1,
TRERF1, TRIM26, ZNF323
CCND3, LY6G6D, MOCS1,
RXRB, TNF, TRIM10
6q23-5 SAMD3, TIAM2, UST, VNN2 EZR
9q31.1 FSD1L, SMC2 ABCA1
10q11 ALOX5, CSTF2T, LOC441666,
RASSF4
ZNF22
10p15.1 AKR1C2, AKR1C3
10q24-26 ATE1, C10orf137, C10orf26,
FAM178A, COX15, CTBP2,
CALHM3, CHST15, PIK3AP1,
SFRP5, SFXN2, SFXN4, TCF7L2,
TRUB1
CNNM2, HTR7, LGI1,
NFKB2, TLL2
11q13 ACY3, ANKRD13D, ARRB1,
CDC42EP2, FOLR3, KCNE3,
MIR194-2, RTN3, RNASEH2C,
SLC25A45, SUV420H1, TPCN2
GSTP1, IGHMBP2, RCE1,
SART1, SLC29A1
12q12-13 AMHR2, LIMA1, TFCP2 APOF, KRT5, KRT75,
KRT81, KRT83, KRT85,
KRT86, VDR
16 Centromeric CHD9, DHODH, ESRP2,
GPR114, GPT2, HN1L,
HPR, ITGAX, LPCAT2,
SCNN1G, SNTB2,
SULT1A2, WWP2
CX3CL1, FOXC2,
MMP15, MT1G,
MT4, NUTF2, TERF2
18p11 FEMA1, MPPE1, ROCK1,
PTPRM
C18ORF1, GRPWe then leveraged our gene expression data to identify chromo-
somal regions with a statistically signiﬁcant proportion of DEGs as an
additional strategy to detect pathogenetically relevant loci. We exam-
ined the chromosomal distribution of the top 200 DEGs (100 most up-
regulated, 100most down-regulated) of the AAblood and skin gene sig-
natures using the “Genome” tool within the dChip software [21]. In
blood, this approach revealed three signiﬁcant AA blood gene expres-
sion “hot spots” on chromosomes 1q21–q32, 11q12–q14, and 16p13–
p13.3 (Fig. 1a) harboring 64 AA DEGs (44 up-regulated, 20 down-
regulated). The transcriptional “hot spot” on 11q was also identiﬁed in
a recent AA GWAS [15]. The 1q21 and 16p13 regions represent novel
chromosomal regions with potential relevance to AA that may warrant
further genetic investigation. See Supplementary Table 1 for a full list of
the AA blood DEGs found within these transcriptional “hot spots”.
Performing the same analysis in skin, we again found three signiﬁ-
cant AA skin gene expression “hot spots” on chromosomes 6p21.3,
12q12-q13, and 17q12-q24 (Fig. 1b) harboring 21 AA lesional skin
DEGs (5 up-regulated, 16 down-regulated). GWAS studies revealed
“hits” at the AA skin transcriptional “hot spots” on 6p and 12q [15],
including 6 genes (1 up-regulated, 5 down-regulated) that localized
within the MHC/HLA region at 6p21, a putative autoimmune disease
susceptibility locus. See Supplementary Table 2 for a full list of the AA
skin DEGs found within these transcriptional “hot spots”. Overall, gene
expression data of AA skin and blood reveals several transcriptional
“hot spots” containing signiﬁcant differential gene expression in
described, and possibly novel, susceptibility loci.
2.2. AA blood gene expression proﬁles differentiate AA patients with a history
of atopy and reveal altered gene expression at suggested atopy susceptibility
loci
While a signiﬁcant proportion of AA patients (up to 60%) have con-
comitant atopic disease, the genetic risk factors for this association are
unknown. Of note, 5 of the 6 transcriptional “hot spots” found within
the AA blood and skin gene expression signatures coincide with regions
previously reported to be relevant to atopic dermatitis (AD) susceptibil-
ity [22,23] (Fig. 1). These data support evidence of a shared genetic
background in patientswith AA and AD. To deconstruct this clinical het-
erogeneity and identify genes and pathways relevant to the develop-
ment of atopy in AA patients, we next compared peripheral blood
gene expression of three AA patientswith a history of atopy (atopic der-
matitis, allergic rhinitis, or asthma) vs. three patients with no prior his-
tory of atopy. To explore the similarities and differences in global gene
expression patterns among the samples without a priori knowledge of
sample identity, we employed an unsupervised hierarchical clustering
method of moderate and high stringency ﬁltering using the 670 and
66 probe sets with the highest variation across samples. This revealed
distinct separation of AA patients based on a history of atopy (Fig. 2),
underscoring the applicability of microarray data for the study of AA
clinical heterogeneity in clinically stratiﬁed patient subgroups.
We found a total of 340 genes (158 up-regulated and 182 down-
regulated) that differentiate AA patients by history of atopy. Ontologic
analysis of these genes reveals an up-regulation of genes involved in
signal transduction, transcriptional regulation, and apoptosis and a
down-regulation of genes involved in cellular adhesion, cell prolifera-
tion, and B cell differentiation in AA patientswith a history of atopic dis-
orders. Analyzing the top 200 DEGs for transcriptional “hot spots”
revealed ﬁve statistically signiﬁcant chromosomal regions located at
3p21–p22, 9p13.3, 12q24, 15q14–q21.2, and 17q21 (Fig. 1c). All but
15q14–q21.2 were previously linked to AD susceptibility. Thirty-three
of the AA with AD DEGs map to one of these hot spots (Fig. 3a) and in-
clude genes involved in transcriptional regulation, cell adhesion regula-
tion, immune system development and response to organic stimuli.
17q21, which harbors 27 type I keratin genes and ﬁve keratin pseudo-
genes [24], is found within an overlapping “hot spot” seen in both AA
skin and AA patients with atopy, underscoring its potential role as a
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list of the AAwith ADDEGs. Finally, several microarray gene expression
studies have evaluated gene expression in AD skin and blood.[25,26].
We compared the 1245 skin and blood AA DEGs revealed in our ana-
lyses [17,18] with 566 previously reported skin and blood AD DEGs
and found 33 overlaps (Table 2). Twenty of the overlapping genes are
up-regulated in both AA and AD patients compared to healthy controls,
while 2 genes are down-regulated in both groups. Eleven genes show
counter-regulation; they are up-regulated in AA patients compared to
controls, but down-regulated in AD patients compared to controls.Fig. 1. Transcriptional “hot spots” in alopecia areata overlap with putative AA and atopy ge
vertical bars. p-Values were calculated for all stretches containing b or = 20 differentially
(of b or = 20 genes) with p b 0.001 were considered “hot spots” of statistical signiﬁcance.
tibility loci as indicated. AA with Atopy (red) = DEGs differentiating AA patients with and w
in blood. AA disease, skin (black) = DEGs differentiating AA patients from controls in skinOverall, these shared genes are involved in inﬂammation, adaptive im-
munity, immune cell trafﬁcking and movement, cell cycle, and lipid
metabolism.
Only a single gene, CALML5 (FC = −2.6), was found to overlap
between the previously reported AD DEGs and 340 DEGs differentiat-
ing AA patients with and without a history of atopy. CALML5, also
known as calmodulin-like skin protein (CLSP), is a skin-speciﬁc
calcium-binding protein directly related to terminal differentiation
in the human epidermis and has been implicated in skin diseases
such as psoriasis [27].netic risk loci. Chromosomal locations of the top 200 DEGs are noted as bolded black
expressed genes to assess the signiﬁcance of “gene proximity”. Signiﬁcant stretches
+ denotes overlap with putative alopecia areata (AA) and atopy (AD) genetic suscep-
ithout atopy. AA disease, blood (blue) = DEGs differentiating AA patients from controls
.
Fig. 2. Unsupervised hierarchical clustering reveals distinct gene expression patterns in
patients with a history of atopy. Unsupervised hierarchical clustering of 66 genes with
the highest variance across samples from 3 AA patients with and 3 patients without a
history of atopy reveals a transcriptional proﬁle unique to AA patients with a history of
atopy. Each row signiﬁes one of the 66 genes, whereas the columns represent samples
processed by a Euclidean distance algorithm in dChip. Expression value intensities are
illustrated by the color scale with a range of −3 to3 on a log2 scale.
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concomitant autoimmune disease
The genetic basis for the development of concurrent autoimmune
(AI) disease is poorly deﬁned. Thus, we compared peripheral blood
gene expression proﬁles of two AA patients with active, concomitant
AI disease to four AA patients without coexisting disease. We found
129 genes were up-regulated and 182 genes were down-regulated in
patients with coexisting AI disease. The majority of these genes are
involved in cytokine signaling and immune cell trafﬁcking, antigen
processing and presentation, and protein modiﬁcation. In mapping
the top 200DEGs (usingmethods described above), we found two tran-
scriptional “hot spots” at 5q23-q31 and 6p21, with 7 of the AA with AI
associatedDEGs localizing to these regions (Fig. 3b). See Supplementary
Table 4 for a full list of the AA with autoimmune disease DEGs.
We also found that the AA blood disease signature (882 DEGs)
contains a subset of 30DEGs in AA patient blood that have been strongly
implicated in the pathogenesis of various autoimmune diseases
(Table 3). These genes are involved in immune and inﬂammatory
response, signal transduction, and cytokine signaling.
2.4. Nail disease in AA
To investigate the genetic elements relevant to nail pathology in AA,
blood gene expression patterns in three AA patients with nail disease
were compared to three patients without nail disease. 129
up-regulated genes and 117 down-regulated genes differentiate these
two groups. Ontologic and pathway analysis revealed dysregulation of
PPAR alpha/RXR alpha signaling, glycosaminoglycan (GAG) synthesis,
structural protein expression, including decreased keratin 40 (KRT40),
and an increased Th2 response in AA patients with nail disease. “Hot
spot” analysis of the top 200 DEGs revealed an over-representation of
transcriptionally altered genes at 5q31.2 and 15q15.3 (Fig. 3c), includ-
ing FGF7 (FC = +2.65), also known as keratinocyte growth factor.
While it is difﬁcult to interpret these results with our current under-
standing of AA associated nail disease, and nail disease in general,
these ﬁndings illuminate a number of genes/pathways of potential
disease relevance. See Supplementary Table 5 for a full list of the AA-
nail DEGs found.
3. Discussion
The genetic investigation of complexmultifactorial diseases remains
difﬁcult with current experimental approaches. In this study, we com-
bined global transcriptional analyses of AA peripheral blood and skin
with various genomic studies, employing an integrated approach to
bridge genetics and gene expression and derive insight into a broad
range of biological processes relevant to disease. This strategy serves
as a ﬁrst step to progress beyond genetic association and towards func-
tional signiﬁcance. Our data illuminate potential molecular links con-
necting putative disease susceptibility loci to phenotypic expression
and clinical heterogeneity.
While the goal of GWAS is to identify potential disease associated
genetic regions, the precise localization of susceptibility loci remains
elusive. For example, a recent AA GWAS identiﬁed Eos (IKZF4) and
ERBB3 as the genes with the strongest association to disease at 12q13.
However, our transcriptional analysis in lesional skin mapped 8 DEGs,
all down-regulated, to this locus, 6 of which are hair keratin genes.
This broad down-regulation of 12q13 genes directly related to AA pa-
thology, i.e. loss of structural proteins essential to hair follicles, suggests
that that the genetic association at 12q13 may (additionally or alterna-
tively) map to one or more of the keratin genes. Overlapping gene ex-
pression data onto GWAS results may help to prioritize candidate
genes for subsequent positional cloning efforts. Combining genetic
and gene expression studies allows a synergy of information to aid in
unraveling the complex interplay between genes and phenotype. It
Fig. 3. Differentially expressed genes within transcriptional “hot spots” found in AA patients with a) a history of atopy, b) a history of concomitant autoimmune disease, or c) nail
disease. Differentially expressed genes in AA patients with a history of atopy (AA-AD)/autoimmunity (AA-AI)/nail disease (AA-ND) vs AA patients without the respective concom-
itant conditions are annotated by chromosomal location. Bars indicate fold-change levels for differentially expressed genes.
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owe their altered expression due to genetic alterations at or near their
coding regions. Thus, AA DEGs overlapping with GWAS susceptibility
loci represent high yield genetic targets for future ﬁnemapping studies.
Moreover, gene expression data provide a functional context to putativegenetic associations, linking them to altered biologic pathways with
clinical relevance.
As an alternate strategy to pinpoint the genetic elements that con-
tribute to disease pathology in AA, we examined gene expression data
from AA blood and skin for chromosomal regions (transcriptional “hot
Table 2
Differentially expressed genes overlapping between AA and AD. Several AA DEGs in our analysis overlap with AD DEGs reported in previous microarray analyses, as listed below.
Numerical fold changes are based on AA blood and skin data, while “+” and “−” indicate up- and down-regulation in previous AD microarray studies, respectively.
Gene Name Entrez gene Fold Change (in AA) Dysregulation in AD
Up-regulation
MS4A6A: membrane-spanning 4-domains, subfamily A, member 6A 64231 10.56 +
HCK: hemopoietic cell kinase 3055 9.71 +
FGL2: ﬁbrinogen-like 2 10875 7.84 +
NDST1: N-deacetylase/N-sulfotransferase 1 3340 7.73 +
TRA@: T cell receptor alpha locus 6955 5.70 +
ITGAX: integrin, alpha X 3687 4.69 +
CD24: CD24 molecule 934 4.53 +
AKR1C2: aldo-keto reductase family 1, member C2 1646 4.53 +
PF4V1: platelet factor 4 variant 1 5197 4.50 +
CD1C: CD1c molecule 911 4.08 +
HN1: hematological and neurological expressed 1 51155 3.78 +
PGLS: 6-phosphogluconolactonase 25796 3.63 +
BCL11A: B-cell CLL/lymphoma 11A 53335 3.63 +
CD58: CD58 molecule 965 3.61 +
ABHD5: abhydrolase domain containing 5 51099 3.51 +
RPS15A: Ribosomal protein S15a 6210 3.39 +
ITPR2: inositol 1,4,5-triphosphate receptor, type 2 3709 2.83 +
RAC2: ras-related C3 botulinum toxin substrate 2 5880 2.77 +
IGFLR1: IGF Like Family Receptor 1 79713 2.53 +
AURKAIP1: aurora kinase A interacting protein 1 54998 2.50 +
Down-regulation
FBXO16: F-box protein 16 55893 -3.81 -
GPD1: glycerol-3-phosphate dehydrogenase 1 (soluble) 2819 -3.97 -
Counter-regulation
DEFA1/DEFA3: defensin, alpha 1/defensin, alpha 3, neutrophil-speciﬁc 1667/1668 8.40 -
CX3CR1: chemokine (C-X3-C motif) receptor 1 1524 8.06 -
FBXL5: F-box and leucine-rich repeat protein 5 26234 4.00 -
LOC730092: RRN3 RNA polymerase I transcription factor homolog pseudogene 730092 3.25 -
ACSL3: acyl-CoA synthetase long-chain family member 3 2181 2.81 -
ACSS2: acyl-CoA synthetase short-chain family member 2 55902 2.71 -
XRCC4: X-ray repair complementing defective repair in Chinese hamster cells 4 7518 2.71 -
C20orf3: chromosome 20 open reading frame 3 57136 2.60 -
HSZFP36: ZFP-36 for a zinc ﬁnger protein 55552 2.55 -
CALML5: calmodulin-like 5 51806 -2.55 +
MMRN2: multimerin 2 79812 -2.97 +
CORIN: corin, serine peptidase 10699 -3.81 +
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to occur by chance. Our goal was to leverage gene expression data to
guide the search for chromosomal regions relevant to AA susceptibility
and pathogenesis. Three of the six “hot spots” detected by our global
transcriptional analysis on 6p, 11q, and 12q overlapped with suscepti-
bility loci determined via genome-wide association (GWAS) and link-
age studies, emphasizing the signiﬁcance of these regions in AA
pathogenesis. Remarkably, all six of these “hot spots” have been previ-
ously described as consensus, or suggested, susceptibility loci in multi-
ple dermatologic and autoimmune disorders, most notably atopic
dermatitis [28–30]. This, however, is the ﬁrst study to date involving
1q21–q32, 16p13, and 17q12–q24 in the pathogenesis of alopecia
areata. Chromosome 1q21 contains the epidermal differentiation com-
plex (EDC), a cluster of genes encoding proteins important for terminal
differentiation in the human epidermis. Variation within EDC genes has
been implicated in the pathogenesis of common skin disorders, includ-
ing atopic dermatitis [31]. Chromosome 16p13 has been recently
labeled a chromosomal regionwith genetic susceptibility factors for au-
toimmune diseases, such as type 1 diabetes, MS, and RA [32]. We noted
the decreased expression of several hair structure-related genes found
at 17q21, including some previously reported to be involved in mono-
genic hair loss disorders such as Monilethrix (KRT81 and KRT86) and
congenital atrichia (VDR)[33]. Their pathogenetic signiﬁcance in AA is
not known. The “hot spots” not previously linked to AA represent
novel regions of potential disease importance, andmaywarrant consid-
eration in future genetic studies.
Furthermore, we found that 5 of the 6 AA altered gene expression
“hot spots” on 1q, 11q, 6p, 12q, and 17q have been previously con-
nected to the susceptibility and pathogenesis of atopic disorders
[29,30,34,35], providing additional support for a shared basis for AAand AD. We examined the link between AA and AD further by compar-
ing gene expression proﬁles of AA patientswith andwithout a history of
atopy. Unsupervised hierarchical clustering revealed distinct gene sig-
natures distinguishing patients based on their history of atopic disor-
ders, providing a means for molecular classiﬁcation through class
prediction (assigning expression proﬁles to known categories of dis-
ease). Further examination revealed “hot spots” of altered gene expres-
sion within previously described atopic disease susceptibility loci at 3p,
9p, 12q, 15q, 17q. A recent study reported an association of ﬁlaggrin
(FLG) gene mutations R501X and 2282del4 in AA patients with comor-
bid atopic dermatitis, particularly in severe forms of AA. Our compari-
son of AA patients with and without atopy did not identify ﬁlaggrin as
a DEG, suggesting themutations may not affect ﬁlaggrin at the gene ex-
pression level. Nevertheless, these ﬁndings have clinical implications
for the identiﬁcation of AA patients at risk for developing AD. In terms
of disease mechanisms, our data highlight a set of overlapping genes
that modulate epidermal differentiation and drive abnormal T-cell re-
sponse relevant to both atopic and autoimmune mechanisms.
Recently, a common cause theory for the development of autoim-
mune diseases has emerged based on shared disease genes and poly-
morphisms. No previous study, however, has shown evidence that AA
may also be implicatedwithin this common cause theory. A comparison
between our list of AA blood associated DEGs list and genes reported to
be altered in other prevalent autoimmune diseases, highlights 30 over-
lapping genes (Table 2), supporting the notion that AA may share a
genetic association with other autoimmune diseases. Many of these
DEGs are involved in immune and inﬂammatory responses, epitomizing
the overactive immune states expected of most autoimmune diseases.
These ﬁndings are further supported by the transcriptional “hot spots”
at 5q31 and 6p21 that were revealed when comparing gene expression
Table 3
Transcriptionally dysregulated genes in AA implicated in systemic and organ-speciﬁc autoimmune diseases. Upregulated AA blood DEGs previously implicated in the pathogenesis
individual or multiple autoimmune diseases are listed and annotated by autoimmune disease.
Gene Entrez gene Fold Change (in AA)
Crohn's disease
TNFSF14: tumor necrosis factor (ligand) superfamily, member 14 8740 5.46
Multiple Sclerosis
CD24: CD24 molecule 934 4.53
ARRB1: arrestin, beta 1 408 4.38
TAC4: tachykinin 4 (hemokinin) 255061 3.73
CCR2: chemokine (C-C motif) receptor 2 1231 3.58
Multple autoimmune diseases
CX3CR1: chemokine (C-X3-C motif) receptor 1 1524 8.06
CD1C: CD1c molecule 911 4.08
PTPN22: protein tyrosine phosphatase, non-receptor type 22 26191 3.16
PTPN6: protein tyrosine phosphatase, non-receptor type 6 5777 2.79
IL12RB1: Interleukin 12 receptor, beta 1 3594 6.63
TNFSF13: tumor necrosis factor (ligand) superfamily, member 13 8741 7.78
TNFRSF1B: tumor necrosis factor receptor superfamily, member 1B 7133 2.66
ITPR2: inositol 1,4,5-triphosphate receptor, type 2 3709 2.83
FCRL3: Fc receptor-like 3 115352 6.02
TRA@: T cell receptor alpha locus 6955 5.70
CIITA: class II, major histocompatibility complex, transactivator 4261 4.20
LTB4R: Leukotriene B4 receptor 1241 4.38
PADI4: peptidyl arginine deiminase, type IV 23569 16.00
CR1: complement component (3b/4b) receptor 1 1378 5.50
Primary biliary cirrhosis
MNDA: myeloid cell nuclear differentiation antigen 4332 9.65
Psoriasis
ALOX5: arachidonate 5-lipoxygenase 240 4.92
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without. 5q31 is home to a well-documented cytokine gene cluster and
susceptibility locus associated with both atopy and psoriasis [36,37],
while the MHC class II region on human chromosome, 6p21, an HLA
class II region, is a known susceptibility locus for several AI diseases
[38]. Taken together, these ﬁndings support a genetic basis for the
increased incidence of coexisting autoimmune diseases in AA patients,
and implicate AA in the common-cause hypothesis [39].
There continues to be amajor gap in our knowledge regarding the ge-
netic basis underlying the extensive clinical heterogeneity that is
observed in complex diseases such as AA. To further understand how
genes are linked to deﬁned clinical phenotypes, we evaluated gene
expression linked with nail disease in AA. The nail shares several
commonalities with hair and its follicle: 1) they are ectodermal struc-
tures; 2) morphologic and anatomical similarities; 3) shared ‘soft’ and
‘hard’ epithelial keratins in hair/nail differentiation [40]. Thus, it is no sur-
prise that various diseases such as AA, psoriasis, lichenplanus, and genet-
ic disorders affect both appendages [41,42]. The list of differentially
expressed genes that distinguish patients affected with nail disease vs.
those that are not affected provide a staring point from which to mine
the genetic and molecular correlates of clinical variation. Interestingly,
KRT40, a gene encoding a type I (acidic) keratin, was down-regulated
in the peripheral blood of AA patients with nail disease as compared to
those without nail disease. KRT40 is expressed in the skin and upper cu-
ticle, however, little else is known regarding its function [43]. We postu-
late that, with larger cohorts and improved cost efﬁciency, microarray
analysis will allow clinical proﬁling of variable parameters, such as risk
of developing nail disease that will likely allow physicians to anticipate,
identify, and treat co-morbidities earlier in the disease course.
In conclusion, this study shows that integrated genome-wide tran-
scriptional and chromosomal proﬁling of alopecia areata is a promising
strategy for mapping of large chromosomally altered regions to identify
loci with altered gene expression that might be biologically meaningful.
Our data provide enhanced insight into the genetic basis of AA clinical
heterogeneity and susceptibility by merging global transcriptionalmicroarray data with genetic data to guide the search for susceptibility
genes. Using this approach, we found that several of the DEGs revealed
by our microarray studies are encoded within putative AA disease loci,
both new and previously described. This list includes a limited set of pre-
viously suggested AA candidate genes and several novel genes. Further,
we located several chromosomal regions of altered gene expression that
are shared between AA and AD, suggesting a possible molecular basis
for the bidirectional increase in risk between atopy and AA identiﬁed in
previous population-based studies [44]. These ﬁndings will ultimately re-
quire analyzing immunohistochemistry and blood protein levels within
larger cohorts to further explore mechanistic questions. Integration of
heterogeneous data fromdisparate technologyplatforms represents a sig-
niﬁcant challenge because of the inconsistencies in gene and protein an-
notations used among different databases, and because the
bioinformatics tools necessary for automated merging of microarray and
proteomic data sets are not yet optimized. Nevertheless, our data suggest
that distinct genetic loci with statistically signiﬁcant altered gene expres-
sion are apparent in peripheral blood and skin, andmay have useful clin-
ical applications relevant to disease classiﬁcation and risk of coexisting
disease.
4. Materials and methods
4.1. Patient recruitment
The study was approved by the Institutional Review Boards (IRB) of
Weil Medical College of Cornell University/New York Hospital (IRB No.
1098-429), and Michigan State University (MSU) (IRB No. 05-1026).
Study subjects were recruited through the National Alopecia Areata
Foundation (NAAF) and the dermatology outpatient clinics at New York
Hospital and Michigan State University. We included peripheral blood
from 18 subjects in this study (Table 1): 9 subjects with AA and 9 healthy
controls. Additionally, a total of 20 biopsies (10 lesional and 10
non-lesional) were used for gene expression analysis of skin from AA
patients. All patients were off therapy for at least 4 weeks and none had
438 A.B. Coda, A.A. Sinha / Genomics 98 (2011) 431–439documented therapy at the site of biopsy. Within the group of peripheral
blood samples, we: 1) compared 3 AA patients with a history of atopy
(including asthma, allergic rhinitis, and/or atopic dermatitis), 2) com-
pared 2 AA patients with a history of autoimmune disease (thyroiditis
and lupus), and 3) compared 3 AA patients with co-morbid nail involve-
ment to 3 AA patients without a history of nail involvement. Informed
written consent was obtained from all study subjects before venous
blood draws. Buffy coat samples were isolated from fresh whole blood
at the time of collection, stored at −80°C, and subsequently used for
RNA extraction. Information regarding demographic data, AA disease
manifestation, current medication, and co-morbid autoimmune diseases
was obtained at the time of blood collection.
4.2. RNA extraction
Total RNA was isolated from buffy coat and skin samples using
TRIzol reagent (Invitrogen, San Diego, CA) per manufacturer's proto-
col. The aqueous phase was isolated and treated with DNase (Qiagen,
Valencia, CA). RNA was then puriﬁed using the RNeasy Mini kit (Qia-
gen). After purifying steps, RNA was eluted with RNase-free water.
The purity and concentration of the ﬁnal RNA product was analyzed
by Nanodrop 100 spectrophotometry (Thermo Scientiﬁc, Waltham,
MA). RNA integrity was assessed by using an RNA Pico Chip with an
Agilent 2100 Bioanalyzer (Agilent Technologies Inc, Palo Alto, CA).
Puriﬁed RNA was stored at−80 °C for up to 30 days until proceeding
with the ampliﬁcation step.
4.3. cDNA production, ampliﬁcation, fragmentation and labeling of cDNA
Puriﬁed RNA was used to produce ﬁrst- and second-strand cDNA
using the WT-OvationTM FFPE RNA Ampliﬁcation system V2 (NuGEN,
San Carlos, CA) by PCR. Double-stranded cDNAwas ampliﬁed according
to manufacturer's instructions and puriﬁed by DNA Clean &
Concentrator-25TM spin columns (Zymo Research, Orange, CA). Only
cDNA of high purity (260/280 ratios: 1.75–2.1) was used for this
study. Fragmenting and labeling of cDNA was performed using
FL-OvationTM cDNA Biotin Module V2 (NuGEN). To assure the success
of fragmentation and size distribution prior to proceeding with micro-
array hybridization, cDNA samples were bioanalyzed before and after
fragmentation and labeling using an RNA 6000 NanoChipTM on the
Agilent Bioanalyzer.
4.4. Microarray analysis
Labeled cDNA samples from the peripheral blood samples were hy-
bridized to Affymetrix HG-U133 Plus 2.0 chips (Affymetrix, Santa Clara,
CA), and then stained on the Affymetrix Fluidics Station 750, and
scanned by the Affymetrix GeneChip Scanner 3000. The U133 Plus 2.0
chip contains more than 54000 probe sets representing more than
33,000 well-characterized genes and UniGenes. For the skin samples,
Fragmented cRNA was hybridized to HG-U95A arrays, screening
12,627 genes. The Affymetrix microarray suite (MAS) 5.0 was used to
obtain gene expression signal values for each gene. Each chipwas scaled
to an average intensity of 500 to adjust forminor variations in the over-
all intensity of hybridization. dChip (www.dchip.org) was then used for
probe-(normalization and modeling) and high-level (hierarchical clus-
tering and sample comparison) analysis. Expression values were log2
transformed and then used to perform an unsupervised hierarchical
clusteringmethod using the probe setswith the highest variation across
samples; for Fig. 2, 66 (high stringency) and 662 (moderate stringency)
probe sets were used. To compare samples and generate a list of differ-
entially expressed genes (DEGs), the following ﬁltering criteria were
used: (i) Benjamini–Hochberg procedure with a 1% false-discovery
rate; (ii) greater than a±2.5 fold change in themean expression values
between the experimental and control groups. Redundant probe sets
for a single gene were then eliminated. Next, we used gene ontologyterms to functionally annotate DEGs, and subsequently perform path-
way discovery analysis using the Database for Annotation, Visualization
and Integrated Discovery (DAVID; http://david.abcc.ncif-crf.gov/) web-
site. Through DAVID, we annotated the gene lists by chromosomal loca-
tion to identify genes within putative genetic risk loci identiﬁed in
recent genome-wide analyses [15,16]. Chromosomal mapping of 200
genes (the 100 genes of highest and lowest fold change, respectively)
assessed for signiﬁcance by generating P-values for all stretches con-
taining b or = 20 differentially expressed genes to assess the signiﬁ-
cance of “gene proximity”. Signiﬁcant stretches (of b or = 20 genes)
wereﬁltered at p b 0.01. In our atopy comparison,we directly compared
gene expression data from three blood and skin AD studies with our
blood and skin DEGs [25,26,45].
Supplementary materials related to this article can be found online
at doi:10.1016/j.ygeno.2011.08.009.
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